These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34715821)

  • 1. Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease.
    Neumann S; Taylor J; Bamford A; Metcalfe C; Gaunt DM; Whone A; Steeds D; Emmett SR; Hollingworth W; Ben-Shlomo Y; Henderson EJ
    BMC Neurol; 2021 Oct; 21(1):422. PubMed ID: 34715821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.
    Henderson EJ; Lord SR; Close JC; Lawrence AD; Whone A; Ben-Shlomo Y
    BMC Neurol; 2013 Dec; 13():188. PubMed ID: 24299497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Henderson EJ; Lord SR; Brodie MA; Gaunt DM; Lawrence AD; Close JC; Whone AL; Ben-Shlomo Y
    Lancet Neurol; 2016 Mar; 15(3):249-58. PubMed ID: 26795874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise- and strategy-based physiotherapy-delivered intervention for preventing repeat falls in people with Parkinson's: the PDSAFE RCT.
    Ashburn A; Pickering R; McIntosh E; Hulbert S; Rochester L; Roberts HC; Nieuwboer A; Kunkel D; Goodwin VA; Lamb SE; Ballinger C; Seymour KC
    Health Technol Assess; 2019 Jul; 23(36):1-150. PubMed ID: 31339100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of augmenting cholinergic function on gait and balance.
    Mancini M; Fling BW; Gendreau A; Lapidus J; Horak FB; Chung K; Nutt JG
    BMC Neurol; 2015 Dec; 15():264. PubMed ID: 26697847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
    Schrag A; Carroll C; Duncan G; Molloy S; Grover L; Hunter R; Brown R; Freemantle N; Whipps J; Serfaty MA; Lewis G
    BMC Neurol; 2022 Dec; 22(1):474. PubMed ID: 36510237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinesterase inhibitors for Parkinson's disease dementia.
    Maidment I; Fox C; Boustani M
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.
    Devos D; Moreau C; Maltête D; Lefaucheur R; Kreisler A; Eusebio A; Defer G; Ouk T; Azulay JP; Krystkowiak P; Witjas T; Delliaux M; Destée A; Duhamel A; Bordet R; Defebvre L; Dujardin K
    J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):668-74. PubMed ID: 24218528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients.
    Li Z; Yu Z; Zhang J; Wang J; Sun C; Wang P; Zhang J
    Eur Neurol; 2015; 74(1-2):86-91. PubMed ID: 26288230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of rivastigmine on neuropsychiatric symptoms in the early stages of Parkinson's disease: A systematic review.
    Reilly S; Dhaliwal S; Arshad U; Macerollo A; Husain N; Costa AD
    Eur J Neurol; 2024 Feb; 31(2):e16142. PubMed ID: 37975761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exercise therapy for prevention of falls in people with Parkinson's disease: a protocol for a randomised controlled trial and economic evaluation.
    Canning CG; Sherrington C; Lord SR; Fung VS; Close JC; Latt MD; Howard K; Allen NE; O'Rourke SD; Murray SM
    BMC Neurol; 2009 Jan; 9():4. PubMed ID: 19161631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventions for preventing falls in Parkinson's disease.
    Allen NE; Canning CG; Almeida LRS; Bloem BR; Keus SH; Löfgren N; Nieuwboer A; Verheyden GS; Yamato TP; Sherrington C
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD011574. PubMed ID: 35665915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow-up.
    van Mierlo TJM; Foncke EMJ; Post B; Schmand BA; Bloem BR; van Harten B; Tissingh G; Munts AG; de Haan RJ; de Bie RMA;
    Brain Behav; 2021 Aug; 11(8):e2257. PubMed ID: 34291590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rivastigmine and Parkinson's disease without dementia : Impact on gait stability and frequency of falling].
    Amadori K
    Z Gerontol Geriatr; 2016 Oct; 49(7):662-663. PubMed ID: 27599816
    [No Abstract]   [Full Text] [Related]  

  • 16. Lisbon Intensive Falls Trampoline Training (LIFTT) Program for people with Parkinson's for balance, gait, and falls: study protocol for a randomized controlled trial.
    Domingos J; Dean J; Fernandes JB; Ramos C; Grunho M; Proença L; Vaz JR; Godinho C
    Trials; 2023 Feb; 24(1):101. PubMed ID: 36755331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of augmenting cholinergic neurotransmission on balance in Parkinson's disease.
    Mancini M; Chung K; Zajack A; Martini DN; Ramsey K; Lapidus J; Horak FB; Nutt JG
    Parkinsonism Relat Disord; 2019 Dec; 69():40-47. PubMed ID: 31675664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine: in Parkinson's disease dementia.
    Siddiqui MA; Wagstaff AJ
    CNS Drugs; 2006; 20(9):739-47; discussion 748-50. PubMed ID: 16953649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial.
    Montero-Odasso M; Wells JL; Borrie MJ; Speechley M
    BMC Neurol; 2009 Aug; 9():42. PubMed ID: 19674471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
    Mamikonyan E; Xie SX; Melvin E; Weintraub D
    Mov Disord; 2015 Jun; 30(7):912-8. PubMed ID: 25914281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.